Global Drugs for Dermatophytosis Market Research Report 2019
Table of Contents
Executive Summary
1 Drugs for Dermatophytosis Market Overview
- 1.1 Product Overview and Scope of Drugs for Dermatophytosis
- 1.2 Drugs for Dermatophytosis Segment by Type
- 1.2.1 Global Drugs for Dermatophytosis Production Growth Rate Comparison by Type (2014-2025)
- 1.2.2 Rx
- 1.2.3 OTC
- 1.3 Drugs for Dermatophytosis Segment by Application
- 1.3.1 Drugs for Dermatophytosis Consumption Comparison by Application (2014-2025)
- 1.3.2 Hospital
- 1.3.3 Clinic
- 1.3.4 Other
- 1.4 Global Drugs for Dermatophytosis Market by Region
- 1.4.1 Global Drugs for Dermatophytosis Market Size Region
- 1.4.2 North America Status and Prospect (2014-2025)
- 1.4.3 Europe Status and Prospect (2014-2025)
- 1.4.4 China Status and Prospect (2014-2025)
- 1.4.5 Japan Status and Prospect (2014-2025)
- 1.5 Global Drugs for Dermatophytosis Market Size
- 1.5.1 Global Drugs for Dermatophytosis Revenue (2014-2025)
- 1.5.2 Global Drugs for Dermatophytosis Production (2014-2025)
2 Global Drugs for Dermatophytosis Market Competition by Manufacturers
- 2.1 Global Drugs for Dermatophytosis Production Market Share by Manufacturers (2014-2019)
- 2.2 Global Drugs for Dermatophytosis Revenue Share by Manufacturers (2014-2019)
- 2.3 Global Drugs for Dermatophytosis Average Price by Manufacturers (2014-2019)
- 2.4 Manufacturers Drugs for Dermatophytosis Production Sites, Area Served, Product Types
- 2.5 Drugs for Dermatophytosis Market Competitive Situation and Trends
- 2.5.1 Drugs for Dermatophytosis Market Concentration Rate
- 2.5.2 Drugs for Dermatophytosis Market Share of Top 3 and Top 5 Manufacturers
- 2.5.3 Mergers & Acquisitions, Expansion
3 Global Drugs for Dermatophytosis Production Market Share by Regions
- 3.1 Global Drugs for Dermatophytosis Production Market Share by Regions
- 3.2 Global Drugs for Dermatophytosis Revenue Market Share by Regions (2014-2019)
- 3.3 Global Drugs for Dermatophytosis Production, Revenue, Price and Gross Margin (2014-2019)
- 3.4 North America Drugs for Dermatophytosis Production
- 3.4.1 North America Drugs for Dermatophytosis Production Growth Rate (2014-2019)
- 3.4.2 North America Drugs for Dermatophytosis Production, Revenue, Price and Gross Margin (2014-2019)
- 3.5 Europe Drugs for Dermatophytosis Production
- 3.5.1 Europe Drugs for Dermatophytosis Production Growth Rate (2014-2019)
- 3.5.2 Europe Drugs for Dermatophytosis Production, Revenue, Price and Gross Margin (2014-2019)
- 3.6 China Drugs for Dermatophytosis Production (2014-2019)
- 3.6.1 China Drugs for Dermatophytosis Production Growth Rate (2014-2019)
- 3.6.2 China Drugs for Dermatophytosis Production, Revenue, Price and Gross Margin (2014-2019)
- 3.7 Japan Drugs for Dermatophytosis Production (2014-2019)
- 3.7.1 Japan Drugs for Dermatophytosis Production Growth Rate (2014-2019)
- 3.7.2 Japan Drugs for Dermatophytosis Production, Revenue, Price and Gross Margin (2014-2019)
4 Global Drugs for Dermatophytosis Consumption by Regions
- 4.1 Global Drugs for Dermatophytosis Consumption by Regions
- 4.2 North America Drugs for Dermatophytosis Consumption (2014-2019)
- 4.3 Europe Drugs for Dermatophytosis Consumption (2014-2019)
- 4.4 China Drugs for Dermatophytosis Consumption (2014-2019)
- 4.5 Japan Drugs for Dermatophytosis Consumption (2014-2019)
5 Global Drugs for Dermatophytosis Production, Revenue, Price Trend by Type
- 5.1 Global Drugs for Dermatophytosis Production Market Share by Type (2014-2019)
- 5.2 Global Drugs for Dermatophytosis Revenue Market Share by Type (2014-2019)
- 5.3 Global Drugs for Dermatophytosis Price by Type (2014-2019)
- 5.4 Global Drugs for Dermatophytosis Production Growth by Type (2014-2019)
6 Global Drugs for Dermatophytosis Market Analysis by Applications
- 6.1 Global Drugs for Dermatophytosis Consumption Market Share by Application (2014-2019)
- 6.2 Global Drugs for Dermatophytosis Consumption Growth Rate by Application (2014-2019)
7 Company Profiles and Key Figures in Drugs for Dermatophytosis Business
- 7.1 Novartis
- 7.1.1 Novartis Drugs for Dermatophytosis Production Sites and Area Served
- 7.1.2 Drugs for Dermatophytosis Product Introduction, Application and Specification
- 7.1.3 Novartis Drugs for Dermatophytosis Production, Revenue, Price and Gross Margin (2014-2019)
- 7.1.4 Main Business and Markets Served
- 7.2 Pfizer
- 7.2.1 Pfizer Drugs for Dermatophytosis Production Sites and Area Served
- 7.2.2 Drugs for Dermatophytosis Product Introduction, Application and Specification
- 7.2.3 Pfizer Drugs for Dermatophytosis Production, Revenue, Price and Gross Margin (2014-2019)
- 7.2.4 Main Business and Markets Served
- 7.3 Sanofi-Aventis
- 7.3.1 Sanofi-Aventis Drugs for Dermatophytosis Production Sites and Area Served
- 7.3.2 Drugs for Dermatophytosis Product Introduction, Application and Specification
- 7.3.3 Sanofi-Aventis Drugs for Dermatophytosis Production, Revenue, Price and Gross Margin (2014-2019)
- 7.3.4 Main Business and Markets Served
- 7.4 Merck
- 7.4.1 Merck Drugs for Dermatophytosis Production Sites and Area Served
- 7.4.2 Drugs for Dermatophytosis Product Introduction, Application and Specification
- 7.4.3 Merck Drugs for Dermatophytosis Production, Revenue, Price and Gross Margin (2014-2019)
- 7.4.4 Main Business and Markets Served
- 7.5 Enzon Pharmaceuticals
- 7.5.1 Enzon Pharmaceuticals Drugs for Dermatophytosis Production Sites and Area Served
- 7.5.2 Drugs for Dermatophytosis Product Introduction, Application and Specification
- 7.5.3 Enzon Pharmaceuticals Drugs for Dermatophytosis Production, Revenue, Price and Gross Margin (2014-2019)
- 7.5.4 Main Business and Markets Served
- 7.6 Bayer
- 7.6.1 Bayer Drugs for Dermatophytosis Production Sites and Area Served
- 7.6.2 Drugs for Dermatophytosis Product Introduction, Application and Specification
- 7.6.3 Bayer Drugs for Dermatophytosis Production, Revenue, Price and Gross Margin (2014-2019)
- 7.6.4 Main Business and Markets Served
- 7.7 Astellas Pharma
- 7.7.1 Astellas Pharma Drugs for Dermatophytosis Production Sites and Area Served
- 7.7.2 Drugs for Dermatophytosis Product Introduction, Application and Specification
- 7.7.3 Astellas Pharma Drugs for Dermatophytosis Production, Revenue, Price and Gross Margin (2014-2019)
- 7.7.4 Main Business and Markets Served
- 7.8 GSK
- 7.8.1 GSK Drugs for Dermatophytosis Production Sites and Area Served
- 7.8.2 Drugs for Dermatophytosis Product Introduction, Application and Specification
- 7.8.3 GSK Drugs for Dermatophytosis Production, Revenue, Price and Gross Margin (2014-2019)
- 7.8.4 Main Business and Markets Served
- 7.9 Abbott
- 7.9.1 Abbott Drugs for Dermatophytosis Production Sites and Area Served
- 7.9.2 Drugs for Dermatophytosis Product Introduction, Application and Specification
- 7.9.3 Abbott Drugs for Dermatophytosis Production, Revenue, Price and Gross Margin (2014-2019)
- 7.9.4 Main Business and Markets Served
8 Drugs for Dermatophytosis Manufacturing Cost Analysis
- 8.1 Drugs for Dermatophytosis Key Raw Materials Analysis
- 8.1.1 Key Raw Materials
- 8.1.2 Price Trend of Key Raw Materials
- 8.1.3 Key Suppliers of Raw Materials
- 8.2 Proportion of Manufacturing Cost Structure
- 8.3 Manufacturing Process Analysis of Drugs for Dermatophytosis
- 8.4 Drugs for Dermatophytosis Industrial Chain Analysis
9 Marketing Channel, Distributors and Customers
- 9.1 Marketing Channel
- 9.1.1 Direct Marketing
- 9.1.2 Indirect Marketing
- 9.2 Drugs for Dermatophytosis Distributors List
- 9.3 Drugs for Dermatophytosis Customers
10 Market Dynamics
- 10.1 Market Trends
- 10.2 Opportunities
- 10.3 Market Drivers
- 10.4 Challenges
- 10.5 Influence Factors
11 Global Drugs for Dermatophytosis Market Forecast
- 11.1 Global Drugs for Dermatophytosis Production, Revenue Forecast
- 11.1.1 Global Drugs for Dermatophytosis Production Growth Rate Forecast (2019-2025)
- 11.1.2 Global Drugs for Dermatophytosis Revenue and Growth Rate Forecast (2019-2025)
- 11.1.3 Global Drugs for Dermatophytosis Price and Trend Forecast (2019-2025)
- 11.2 Global Drugs for Dermatophytosis Production Forecast by Regions (2019-2025)
- 11.2.1 North America Drugs for Dermatophytosis Production, Revenue Forecast (2019-2025)
- 11.2.2 Europe Drugs for Dermatophytosis Production, Revenue Forecast (2019-2025)
- 11.2.3 China Drugs for Dermatophytosis Production, Revenue Forecast (2019-2025)
- 11.2.4 Japan Drugs for Dermatophytosis Production, Revenue Forecast (2019-2025)
- 11.3 Global Drugs for Dermatophytosis Consumption Forecast by Regions (2019-2025)
- 11.3.1 North America Drugs for Dermatophytosis Consumption Forecast (2019-2025)
- 11.3.2 Europe Drugs for Dermatophytosis Consumption Forecast (2019-2025)
- 11.3.3 China Drugs for Dermatophytosis Consumption Forecast (2019-2025)
- 11.3.4 Japan Drugs for Dermatophytosis Consumption Forecast (2019-2025)
- 11.4 Global Drugs for Dermatophytosis Production, Revenue and Price Forecast by Type (2019-2025)
- 11.5 Global Drugs for Dermatophytosis Consumption Forecast by Application (2019-2025)
12 Research Findings and Conclusion
13 Methodology and Data Source
- 13.1 Methodology/Research Approach
- 13.1.1 Research Programs/Design
- 13.1.2 Market Size Estimation
- 13.1.3 Market Breakdown and Data Triangulation
- 13.2 Data Source
- 13.2.1 Secondary Sources
- 13.2.2 Primary Sources
- 13.3 Author List
Ringworm on the skin like athlete's foot (tinea pedis) and jock itch (tinea cruris) can usually be treated with non-prescription antifungal creams, lotions, or powders applied to the skin for 2 to 4 weeks.
The global Drugs for Dermatophytosis market is valued at xx million US$ in 2018 is expected to reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.
This report focuses on Drugs for Dermatophytosis volume and value at global level, regional level and company level. From a global perspective, this report represents overall Drugs for Dermatophytosis market size by analyzing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan.
At company level, this report focuses on the production capacity, ex-factory price, revenue and market share for each manufacturer covered in this report.
The following manufacturers are covered:
Novartis
Pfizer
Sanofi-Aventis
Merck
Enzon Pharmaceuticals
Bayer
Astellas Pharma
GSK
Abbott
Segment by Regions
North America
Europe
China
Japan
Segment by Type
Rx
OTC
Segment by Application
Hospital
Clinic
Other